Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Puma Biotechnology (PBYI)

Puma Biotechnology (PBYI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 375,607
  • Shares Outstanding, K 40,258
  • Annual Sales, $ 225,110 K
  • Annual Income, $ -60,000 K
  • 60-Month Beta 1.31
  • Price/Sales 1.69
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade PBYI with:

Options Overview

Details
  • Implied Volatility 97.71%
  • Historical Volatility 58.07%
  • IV Percentile 17%
  • IV Rank 35.18%
  • IV High 154.77% on 08/05/20
  • IV Low 66.74% on 03/17/21
  • Put/Call Vol Ratio 0.26
  • Today's Volume 63
  • Volume Avg (30-Day) 90
  • Put/Call OI Ratio 0.40
  • Today's Open Interest 3,051
  • Open Int (30-Day) 879

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate 0.32
  • Number of Estimates 2
  • High Estimate 0.39
  • Low Estimate 0.26
  • Prior Year -0.43
  • Growth Rate Est. (year over year) +174.42%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.02 +5.10%
on 04/12/21
11.60 -18.28%
on 03/15/21
-1.81 (-16.03%)
since 03/12/21
3-Month
9.02 +5.10%
on 04/12/21
14.14 -32.96%
on 02/10/21
-1.31 (-12.14%)
since 01/13/21
52-Week
7.48 +26.74%
on 11/06/20
14.14 -32.96%
on 02/10/21
+1.09 (+12.99%)
since 04/13/20

Most Recent Stories

More News
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on April 12, 2021 the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted...

PBYI : 9.48 (-1.46%)
Celcuity (CELC) Soars on Agreement With Pfizer & Study Data

Celcuity (CELC) is developing gedatolisib in combination with Pfizer's Ibrance and an endocrine therapy in breast cancer patients. It inks deal to gain exclusive rights to gedatolisib from Pfizer.

PFE : 37.16 (+0.51%)
NVS : 86.61 (-0.84%)
PBYI : 9.48 (-1.46%)
CELC : 27.03 (-3.26%)
TYME Announces Appointment of Dr. Jan M Van Tornout as Acting Chief Medical Officer

Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs(TM)), today announced the appointment of Jan M Van Tornout, MD, MSc, as acting...

ALPMF : 14.7000 (-0.64%)
CYCC : 6.86 (-3.65%)
GSK : 36.04 (-0.06%)
INO : 8.73 (+5.95%)
PBYI : 9.48 (-1.46%)
TYME : 1.5400 (+0.65%)
Puma Biotech (PBYI) Down 6.3% Since Last Earnings Report: Can It Rebound?

Puma Biotech (PBYI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

PBYI : 9.48 (-1.46%)
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on March 4, 2021 the Compensation Committee of Puma's Board of Directors approved the grant of an inducement restricted...

PBYI : 9.48 (-1.46%)
Puma Biotechnology to Present at the Barclays Global Healthcare Conference

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the...

PBYI : 9.48 (-1.46%)
Puma Biotechnology to Present at the H.C. Wainwright Global Life Sciences Conference

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the...

PBYI : 9.48 (-1.46%)
Puma (PBYI) Q4 Loss Wider Than Expected, Nerlynx Sales Fall

Puma Biotech (PBYI) reports wider-than-expected fourth-quarter loss while sales beat estimates.

RHHBY : 41.6900 (+0.29%)
ACOR : 4.16 (+1.96%)
MRNA : 149.71 (+7.40%)
PBYI : 9.48 (-1.46%)
CANbridge Pharmaceuticals and Puma Biotechnology Agree to Terminate NERLYNX(R) License Agreement and Settle Arbitration

CANbridge Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing drug candidates in China and North Asia, and Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical...

PBYI : 9.48 (-1.46%)
Puma Biotech: 4Q Earnings Snapshot

LOS ANGELES (AP) _ Puma Biotechnology Inc. (PBYI) on Thursday reported a loss of $15 million in its fourth quarter.

PBYI : 9.48 (-1.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Puma Biotechnology, Inc. is a biopharmaceutical company focused on the acquisition, in-licensing, development and commercialization of novel therapeutics for the treatment of cancer. Its products under development include PB272 (oral neratinib) for the treatment of patients with human epidermal growth...

See More

Key Turning Points

3rd Resistance Point 10.26
2nd Resistance Point 10.00
1st Resistance Point 9.74
Last Price 9.48
1st Support Level 9.23
2nd Support Level 8.97
3rd Support Level 8.71

See More

52-Week High 14.14
Fibonacci 61.8% 11.60
Fibonacci 50% 10.81
Fibonacci 38.2% 10.02
Last Price 9.48
52-Week Low 7.48

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar